Completed Enrollment
Abemaciclib Plus Darolutamide in Prostate Cancer That Has Spread After Initial Treatment
I3Y-MC-JPEI - ClinicalTrials.gov - NCT05999968
The main purpose of this study is to learn more about the safety and tolerability of abemaciclib when given in combination with darolutamide to participants with prostate cancer that has spread after initial treatment.
Trial Summary
Age Range
≥18 yearsConditions the trial is for
Prostate CancerWhat the trial is testing?
Abemaciclib, Darolutamide, LHRH agonist/antagonistCould I receive a Placebo?
NoEnrollment Goal
10Trial Dates
Jan 12, 2024 - Jul 2026How long will I be in the trial?
Participation may last up to 32 months.Trial Phase
IKey Requirements
Clinical trials have inclusion and exclusion requirements to determine which individuals qualify for participation. Listed below are key requirements for this clinical trial, but there may be additional requirements to qualify.Participants Must:
Have a diagnosis of prostate cancer that has spread to other parts of the body and no longer responds to treatment to lower testosterone
Have blood test results that show that body organs are working appropriately
Be well enough to walk and do light work
Participants Must Not:
Have had certain prior treatments for prostate cancer
Have serious medical conditions, such as heart disease
Lilly Trial Alerts
Sign up to receive updates about new trials and find out when a clinical trial site near you starts enrolling.
Clinical Trial Resources
You will complete the questionnaire on another website.YesNo